Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Trastornos del Movimiento

3827 ARTÍCULOS , VIENDO DEL 2506 AL 2520

Liver X receptors, nervous system, and lipid metabolism

Cermenati G, Brioschi E, Abbiati F, Melcangi RC, Caruso D, Mitro N.

J Endocrinol Invest. 2013 Jun;36(6):435-43. doi: 10.3275/8941. Epub 2013 Apr 18.

The unresolved puzzle why alanine extensions cause disease

Winter R, Liebold J, Schwarz E.

Biol Chem. 2013 Aug;394(8):951-63. doi: 10.1515/hsz-2013-0112.

[The White man's burden - a case study caught between bipolar affective disorder and Huntington's disease]

Nowidi K, Kunisch R, Bouna-Pyrrou P, Meißner D, Hennig-Fast K, Weindl A, Förster S, Neuhann TM, Falkai P, Berger M, Musil R.

Fortschr Neurol Psychiatr. 2013 Jun;81(6):337-45. doi: 10.1055/s-0033-1335040. Epub 2013 Apr 23.

The cell biology of prion-like spread of protein aggregates: mechanisms and implication in neurodegeneration

Costanzo M, Zurzolo C.

Biochem J. 2013 May 15;452(1):1-17. doi: 10.1042/BJ20121898.

Successful deep brain stimulation surgery with intraoperative magnetic resonance imaging on a difficult neuroacanthocytosis case: case report

Lim TT, Fernandez HH, Cooper S, Wilson KM, Machado AG.

Neurosurgery. 2013 Jul;73(1):E184-7; discussion E188. doi: 10.1227/01.neu.0000429852.45073.73.

8OHdG is not a biomarker for Huntington disease state or progression

Borowsky B, Warner J, Leavitt BR, Tabrizi SJ, Roos RA, Durr A, Becker C, Sampaio C, Tobin AJ, Schulman H.

Neurology. 2013 May 21;80(21):1934-41. doi: 10.1212/WNL.0b013e318293e1a1. Epub 2013 Apr 24.

Clinical neurophysiology in movement disorders

Apartis E.

Handb Clin Neurol. 2013;111:87-92. doi: 10.1016/B978-0-444-52891-9.00008-7.

Immune-mediated extrapyramidal movement disorders, including Sydenham chorea

Dale RC.

Handb Clin Neurol. 2013;112:1235-41. doi: 10.1016/B978-0-444-52910-7.00046-5.

Huntington's disease in children

Letort D, Gonzalez-Alegre P.

Handb Clin Neurol. 2013;113:1913-7. doi: 10.1016/B978-0-444-59565-2.00061-7.

Redefining the genetic risk for Huntington disease

Feigin A.

Neurology. 2013 May 28;80(22):2004-5. doi: 10.1212/WNL.0b013e318294b49b. Epub 2013 Apr 26.

Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS

Killoran A, Biglan KM, Jankovic J, Eberly S, Kayson E, Oakes D, Young AB, Shoulson I.

Neurology. 2013 May 28;80(22):2022-7. doi: 10.1212/WNL.0b013e318294b304. Epub 2013 Apr 26.

LXR agonists: new potential therapeutic drug for neurodegenerative diseases

Xu P, Li D, Tang X, Bao X, Huang J, Tang Y, Yang Y, Xu H, Fan X.

Mol Neurobiol. 2013 Dec;48(3):715-28. doi: 10.1007/s12035-013-8461-3. Epub 2013 Apr 27.

Transcranial magnetic stimulation of degenerating brain: a comparison of normal aging, Alzheimer's, Parkinson's and Huntington's disease

Ljubisavljevic MR, Ismail FY, Filipovic S.

Curr Alzheimer Res. 2013 Jul;10(6):578-96. doi: 10.2174/15672050113109990133.

Optogenetic insights into striatal function and behavior

Lenz JD, Lobo MK.

Behav Brain Res. 2013 Oct 15;255:44-54. doi: 10.1016/j.bbr.2013.04.018. Epub 2013 Apr 28.

Circulating microRNAs: a novel class of potential biomarkers for diagnosing and prognosing central nervous system diseases

Jin XF, Wu N, Wang L, Li J.

Cell Mol Neurobiol. 2013 Jul;33(5):601-13. doi: 10.1007/s10571-013-9940-9. Epub 2013 Apr 30.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias